Jump to content

Neil Blumberg

  • Posts

  • Joined

  • Last visited

  • Days Won

  • Country

    United States

Neil Blumberg last won the day on September 20

Neil Blumberg had the most liked content!

Profile Information

  • Gender
  • Occupation
    Hematologist/Transfusion Medicine Physician

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

Neil Blumberg's Achievements

  1. We offer RhIgG to Rh negative patients who are female and <50 years old who receive Rh pos products, whether plasma or platelets.
  2. Those are theoretical constructs. The data suggest fresh isn't best if there are more infections as there have been in randomized trials of fresh vs. average storage period. More study needed, but the data are more important than the dogma. Infection is the most common cause of morbidity and mortality in all hospital patients, including newborns.
  3. Sickle trait cells do not sickle under physiologic conditions compatible with life. Purely a theoretical construct. Oxygen transport is also normal under physiologic conditions compatible with life. The evidence that sickle trait cells present any risks to any patient through transfusion is exactly zero. Patients with sickle trait rarely, if ever, have any problems attributable to sickle trait. The epidemiologic evidence is likewise weak, if not zero.
  4. There is reason NOT to use the freshest possible units. They may be more toxic than intermediate stored units. This is something that made sense but was almost certainly wrong. See below for the reasoning and published data. We use <21 days as fresh for this reason and avoid <7 days storage for everyone based upon the randomized trial data. BMJ 2019;366:l4968 doi: 10.1136/bmj.l4968 (Published 5 August 2019) Page 1 of 1 Letters Trivella and colleagues present some caveats around the subject of duration of red cell storage and clinical outcomes.1 Studies have been widely interpreted as showing that transfusion is not associated with adverse clinical outcomes. I think this is a serious misinterpretation of the data. In addition to the concerns raised by the authors, another valid hypothesis, which has received little attention, is that very short storage red cells might be more dangerous than medium storage periods (say 7-21 days) and equally dangerous as longer storage red cells (say 28-42 days). An inverted U shaped curve. The evidence for this comes from a meta-analysis finding that “ultra short” storage of red cells was associated with a post-transfusion increase in nosocomial infection.2 Shorter storage red cells have a greater imbalance of oxidation-reduction potential than longer storage red cells in preliminary studies in vitro.3 Red cell storage duration is also a poor predictor of post-transfusion free haemoglobin and heme, putative mediators of toxicity from transfusions.4 5 We need better metrics for predicting red cell transfusion efficacy and toxicity. The simple expedient of fresher red cells is clearly not that metric and might be leading us to transfuse more toxic red cells (very fresh) in the most fragile patients, such as premature newborns. A new approach is clearly called for by the current data. At our centre we define fresh as <21 days of storage, and we generally never transfuse a red cell that has been stored for much less than 7-10 days, for the above reasons as well as logistics of supply. Competing interests: None declared. 1 Trivella M, Stanworth SJ, Brunskill S, Dutton P, Altman DG. Can we be certain that storage duration of transfused red blood cells does not affect patient outcomes?BMJ 2019;365:l2320. 10.1136/bmj.l2320 31186250 2 Alexander PE, Barty R, Fei Y, etal . Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. Blood 2016;127:400-10. 10.1182/blood-2015-09-670950 26626995 3 Schmidt A, Gore E, Cholette JM, etal . Oxidation reduction potential (ORP) is predictive of complications following cardiac surgery in pediatric patients[abstract]. Transfusion 2016;56(Supplement S4):20A-1A. 4 Cholette JM, Pietropaoli AP, Henrichs KF, etal . Elevated free hemoglobin and decreased haptoglobin levels are associated with adverse clinical outcomes, unfavorable physiologic measures, and altered inflammatory markers in pediatric cardiac surgery patients. Transfusion 2018;58:1631-9. 10.1111/trf.14601 29603246 5 Pietropaoli AP, Henrichs KF, Cholette JM, etal . Total plasma heme concentration increases after red blood cell transfusion and predicts mortality in critically ill medical patients. Transfusion 2019;59:2007-15. 10.1111/trf.15218 30811035 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/ permissions LETTERS
  5. If the unit if leukoreduced, as all red cell transfusions should be, there is no need for CMV negative in my view.
  6. This is a clinical call that we make between the senior medical technical staff present and the attending physician. We routinely switch male patients, and older females who are Rh negative to Rh positive red cells when transfusion rate is significant and supply constrained. No policy. Just a clinical decision, which we communicate to the treating team. Typically a liver transplant that has gone badly, an exsanguinating trauma patient and similar situations.
  7. We use either ABO identical or washed O red cells. Usually volume reduced so the hematocrit is around 70-80% either by centrifugation or washing with Plasmalyte. We have data that saline washing is likely associated with more hemolysis and metabolic acidosis. Leukoreduced and <21 days old. We prefer not to use the very short storage red cells (<7 days) as there is evidence they are more dangerous from randomized trials, albeit in mostly adult patients. We do not CMV test or test for hemoglobin S, except for exchange transfusions. No evidence that hemoglobin S trait is a problem for transfusion in any situation, but particularly for smaller volume transfusions. We do irradiate for newborns since immunodeficiencies, while very rare, are often not diagnosed until later in infancy or early childhood.
  8. In New York State, we also are inspected by the state. FDA, NY State, AABB, CAP. You can make a sound argument that this is wasteful and duplicative. Obviously we don't have any choice about FDA and NY State. CAP and AABB, as accreditation organizations, will accept the results of each other's inspections, which is a plus, but you are still dealing with two sets of requirements. My advice to smaller facilities is to pick one if you can do so, and not duplicate your efforts and expense. Both organizations are essentially trade organizations, not scholarly/research societies. They both provide important educational opportunities, but you don't need both to keep your staff current, in my view. With the shortage of medical technologists, reducing non-productive non-clinical effort is a priority to prevent staff burnout and keep everyone focused on the main mission, patient care.
  9. Amen to the comments above. 28% is pretty good. About 5% of our patients have antibodies detectable in the indirect antiglobulin test, so we'd rather receive more samples rather than fewer.
  10. If there is detectable anti-D in the antibody screen, would usually transfuse Rh negative blood, although the risk of clinically significant hemolysis is low. We do not know that mild hemolysis is benign, for one thing. As for "freshness" this turns out to be one of the things we got totally wrong. Fresher blood (<7 days say) is probably less safe for reasons unknown than blood stored 7-21 days. Fresher blood is associated with increased infections in the recipient in randomized trials, so our approach to this in our center has turned 180 degrees. We prefer not to use <7 day old red cells, but define fresh as 7-21 days. Randomized trial data. Thus in your situation I would strongly prefer 7-21 day old Rh negative red cells to giving <7 or <5 or whatever Rh positive red cells to a child with anti-D from Rh IgG. Freshness is harmful nonsense with a long history of expert opinion that, regrettably has been proven wrong by data.
  11. Bottom line is believe the lab test results (data) and make clinical decisions weighing the risks and benefits :). A patient who has anti-K (mimicking, auto, passive, or otherwise) should receive K negative red cells.
  12. The observation that antigen negative cells can yield an eluate with an antibody for an antigen not present has been known for more than half a century I believe. It's often referred to as the Matuhasi-Ogata phenomenon, first reported in the 1950s and 1960s. My mentor, Joe Bove and Patrick Mollison wrote about this a bit later in the 1970s based upon work Bove did during a sabbatical in London. Needless to say, I heard about this often as a resident physician under Bove's supervision :). Brings back memories.... Immunology,1973,25,793. Non-specificBindingofIgGtoAntibody-coated RedCells (The'Matuhasi-OgataPhenomenon') J.R.BOVE,*A.M.HOLBURNANDP.L.MOLLISON MRCExperimentalHaematologyUnit, StMary'sHospitalMedicalSchool,LondonW21PG Summary.Severalobservershavereportedthatredcellscoatedwithaspecific blood-groupantibodymaytakeupasecondblood-groupantibodynon-specifically, aneffectknownasthe'Matuhasi-Ogataphenomenon'.Inthepresentwork, thiseffectwasinvestigatedusingeither'25I-labelledantibodiesofvarious specificitiesora1311-labelledpreparationofIgGlackingrelevantantibodies.In confirmationofmuchpreviouswork,itwasfoundthatredcellstookupappreciableamountsofIgGnon-specifically;however,thisuptakewasnotincreased bypreviouscoatingoftheredcellswithspecificantibody.WhentheIgGtakenup non-specificallyincludedablood-groupantibodyinrelativelyhighconcentration, aneluatesubsequentlypreparedfromtheredcellscontainedsufficientoftheantibodytobedetectable.Thus,thefindingofunexpectedantibodiesineluatesmay beduetonon-specificuptakeofIgGratherthantoadherenceofantibodiesto antigen-antibodycomplexes.
  13. Why would you want to transfuse blood at such a high rate? Perhaps I'm misunderstanding, but I would never transfuse a patient who wasn't exsanguinating at 300 ml/min. And having that level of flow isn't necessary for transfusion, so I'm a bit clueless about why you picked that number. It's a dialysis issue, not a transfusion issue, no? Vascular access is not the transfusion service's purview, in general, so I'm not clear why you are concerned. Have you had lots of red cells returned because they didn't have vascular access?
  14. Thanks Malcolm. One issue with a very long life is that few are left who remember you. Larry was a remarkable and important contributor to progress in transfusion medicine, particularly on the subject of autoimmune hemolytic anemias, along with his long time collaborator, the late George Garratty. I remember both of them well and wish peace to their family and friends.
  15. All potentially clinically significant antibodies like this can be managed pretty well by non-invasive fetal monitoring for anemia by ultrasound (doppler velocity), so the management should be the same for all such antibodies. Clinical variation is great, as you all know, so the drill is to monitor the fetus. No anemia, no worries. Anemia leads to intervention. Serology is largely irrelevant (e.g., titers) but habit is to measure them by most clinicians.
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.